אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

novartis ireland limited - mycophenolic acid - gastro-resistant tablet - 360 milligram(s) - selective immunosuppressants; mycophenolic acid

מלזיה - אנגלית - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - mycophenolic acid (as sodium salt) -

ארצות הברית - אנגלית - NLM (National Library of Medicine)

avera mckennan hospital - mycophenolate sodium (unii: wx877sqi1g) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolic acid 180 mg

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate sodium, quantity: 384.8 mg (equivalent: mycophenolic acid, qty 360 mg) - tablet, enteric coated - excipient ingredients: crospovidone; hypromellose; triethyl citrate; magnesium stearate; maize starch; silicon dioxide; povidone; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - - indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants. ,- indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate sodium, quantity: 384.8 mg (equivalent: mycophenolic acid, qty 360 mg) - tablet, enteric coated - excipient ingredients: triethyl citrate; maize starch; crospovidone; hypromellose; magnesium stearate; silicon dioxide; povidone; lactose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - - indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants. ,- indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis.

קנדה - אנגלית - Health Canada

novartis pharmaceuticals canada inc - mycophenolic acid (mycophenolate sodium) - tablet (enteric-coated) - 180mg - mycophenolic acid (mycophenolate sodium) 180mg - immunosuppressive agents

קנדה - אנגלית - Health Canada

novartis pharmaceuticals canada inc - mycophenolic acid (mycophenolate sodium) - tablet (enteric-coated) - 360mg - mycophenolic acid (mycophenolate sodium) 360mg - immunosuppressive agents

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 384.8 mg - tablet, enteric coated - excipient ingredients: crospovidone; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide red; hypromellose phthalate; iron oxide yellow; povidone; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 192.4 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; hypromellose phthalate; maize starch; indigo carmine; povidone; titanium dioxide; magnesium stearate; crospovidone; iron oxide yellow; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

הממלכה המאוחדת - אנגלית - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - mycophenolate sodium - gastro-resistant tablet - 180mg